MPDZ as a Novel Epigenetic Silenced Tumor Suppressor Inhibits Growth and Progression of Lung Cancer through the Hippo-YAP Pathway

The tumor suppressing effects of MPDZ were determined in vitro and in vivo. The target molecules and signaling pathway that mediated the function of MPDZ were also identified.
[Oncogene]
Liu, W., Huang, Y., Wang, D., Han, F., Chen, H., Chen, J., Jiang, X., Cao, J., & Liu, J. (2021). MPDZ as a novel epigenetic silenced tumor suppressor inhibits growth and progression of lung cancer through the Hippo-YAP pathway. Oncogene, 1–18. https://doi.org/10.1038/s41388-021-01857-8 Cite
Full Article
Bookmark

No account yet? Register

0
Share

FOXH1 Promotes Lung Cancer Progression by Activating the Wnt/β-Catenin Signaling Pathway

A549 and PC9 cells were transfected with short hairpin RNA targeting FOXH1 mRNA. The Cell Counting Kit-8, colony formation, soft agar, wound healing, transwell invasion and flow cytometry assays were performed to evaluate proliferation, migration and invasion of lung cancer cells.
[Cancer Cell International]
Zhang, J., Zhang, X., Yang, S., Bao, Y., Xu, D., & Liu, L. (2021). FOXH1 promotes lung cancer progression by activating the Wnt/β-catenin signaling pathway. Cancer Cell International, 21(1), 293. https://doi.org/10.1186/s12935-021-01995-9 Cite
Full Article
Bookmark

No account yet? Register

0
Share

PB01 Suppresses Radio-Resistance by Regulating ATR Signaling in Human Non-Small-Cell Lung Cancer Cells

Scientists reported the antitumor effects and mechanism of a novel benzothiazole derivative 4-methoxy-cyclohexane carboxylic acid [2-(3,5-dimethyl-isoxazole-4-yl) sulpanil-benzothiazole-6-yl]-amide (PB01) in radiation-resistant human non-small-cell lung cancer cells.
[Scientific Reports]
Kim, T. W., Hong, D.-W., & Hong, S. H. (2021). PB01 suppresses radio-resistance by regulating ATR signaling in human non-small-cell lung cancer cells. Scientific Reports, 11(1), 12093. https://doi.org/10.1038/s41598-021-91716-z Cite
Full Article
Bookmark

No account yet? Register

0
Share

Hyperbaric Oxygen Suppressed Tumor Progression through the Improvement of Tumor Hypoxia and Induction of Tumor Apoptosis in A549-Cell-Transferred Lung Cancer

Reserachers investigated the effects of hyperbaric oxygen treatment (HBOT) on solid tumors, such as lung cancer. Non-small cell human lung carcinoma A549-cell-transferred severe combined immunodeficiency mice were selected as an in vivo model to detect the potential mechanism of HBOT in lung tumors.
[Scientific Reports]
Chen, S.-Y., Tsuneyama, K., Yen, M.-H., Lee, J.-T., Chen, J.-L., & Huang, S.-M. (2021). Hyperbaric oxygen suppressed tumor progression through the improvement of tumor hypoxia and induction of tumor apoptosis in A549-cell-transferred lung cancer. Scientific Reports, 11(1), 12033. https://doi.org/10.1038/s41598-021-91454-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion with Heterogeneous Mechanisms and Treatment Considerations

In this review, the authors focus on examining the pathogenesis of Connective tissue disease related interstitial lung disease with respect to genetics, environmental factors, and immunological factors.
[Frontiers in Immunology]
Shao, T., Shi, X., Yang, S., Zhang, W., Li, X., Shu, J., Alqalyoobi, S., Zeki, A. A., Leung, P. S., & Shuai, Z. (2021). Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.684699 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Mesenchymal Growth Hormone Receptor Deficiency Leads to Failure of Alveolar Progenitor Cell Function and Severe Pulmonary Fibrosis

The authors identified growth hormone receptor is mainly expressed in mesenchymal cells, and its expression is substantially decreased in idiopathic pulmonary fibrosis lungs.
[Science Advances]
Full Article
Bookmark

No account yet? Register

0
Share

Harnessing Organs-on-a-Chip to Model Tissue Regeneration

The authors discussed the potential of “organ-on-a-chip” systems to study regenerative therapies with focus on three distinct organ systems: cardiac, respiratory, and hematopoietic.
[Cell Stem Cell]
Tavakol, D. N., Fleischer, S., & Vunjak-Novakovic, G. (2021). Harnessing organs-on-a-chip to model tissue regeneration. Cell Stem Cell, 28(6), 993–1015. https://doi.org/10.1016/j.stem.2021.05.008 Cite
Abstract
Bookmark

No account yet? Register

0
Share

4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update

4D pharma plc announced the completion of its target enrollment of 30 patients for Part A of its Phase I/II clinical trial of MRx-4DP0004 in patients with partly-controlled asthma.
[4D pharma plc]
Press Release
Bookmark

No account yet? Register

0
Share

Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma

Researchers examined the ability of patient-derived organoids to predict clinical responses to targeted therapies in individual patients and to identify effective anti-cancer therapies for novel molecular targets.
[Clinical Cancer Research]
Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma | Clinical Cancer Research. (n.d.). Retrieved June 4, 2021, from https://clincancerres.aacrjournals.org/content/early/2021/06/03/1078-0432.CCR-20-5026 Cite
Abstract
Bookmark

No account yet? Register

0
Share

In Situ Vitrification of Lung Cancer Organoids on a Microwell Array

Investigators described a novel in situ cryopreservation technology on the superhydrophobic microwell array chip-chip to preserve the viability of the organoids for future drug sensitivity tests.
[Micromachines]
Liu, Q., Zhao, T., Wang, X., Chen, Z., Hu, Y., & Chen, X. (2021). In Situ Vitrification of Lung Cancer Organoids on a Microwell Array. Micromachines, 12(6), 624. https://doi.org/10.3390/mi12060624 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Rubedo Life Sciences Establishes Collaboration with Cedars-Sinai Medical Center to Advance Idiopathic Pulmonary Fibrosis Program

Rubedo Life Sciences, Inc. a drug discovery company announced a collaboration with Cedars-Sinai Medical Center in Los Angeles, to advance its idiopathic pulmonary fibrosis (IPF) program and establish collaborative studies.
[Rubedo Life Sciences, Inc. (Business Wire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share
Share